Trailing-twelve-month (TTM) revenue is $1.66 Billion with a year-over-year growth of +41.15%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $354,264,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-03 |
| Q4 FY2025Period ended 2025-12-31 | $451,767,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-17 |
| Q1 FY2026Period ended 2026-03-31 | $376,708,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $480,999,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $1,663,738,000 |
Current P/S: $12,788,426,653 market capitalization ÷ $1,663,738,000 TTM revenue = 7.69x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:25:07.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $481.00M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:26:41.144Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| bulk rHuPH20 | $38M | $81M | $82M | N/A | N/A | N/A |
| Bulk rHuPH20 | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132013-12-31 · USD | FY20142014-12-31 · USD | FY20152015-12-31 · USD | FY20162016-12-31 · USD | FY20172017-12-31 · USD | FY20182018-12-31 · USD |
|---|---|---|---|---|---|---|
| Foreign Countries | $36M | $1M | $772,000 | $1M | N/A | N/A |
| SWITZERLAND | $35M | $43M | $57M |
$1.66B
$1.66 Billion
+41.15%
vs. $1.18B a year ago (TTM)
+32.18%
5 Year compound annual growth rate
1 Year
+41.15%
3 Year
+29.07%
5 Year
+32.18%
10 Year
+27.31%
15 Year
+28.72%
20 Year
+54.57%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.40B | +$381.29M | +37.55% |
| 2024 | $1.02B | +$186.07M | +22.44% |
| 2023 | $829.25M | +$169.14M | +25.62% |
| 2022 | $660.12M | +$216.81M | +48.91% |
| 2021 | $443.31M | +$175.72M | +65.67% |
| 2020 |
TTM Growth
+41.15%
3-Year CAGR
+29.07%
5-Year CAGR
+32.18%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:26:41.144Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2018-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $115M |
| $86M |
| $133M |
| Collaborative Agreements | $123M | $135M | $109M | $81M | $141M | $152M |
|---|
| Development Fees | $70M | $42M | $59M | N/A | N/A | N/A |
|---|
| ENHANZE drug product | $719,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Hylenex Recombinant | $17M | $23M | N/A | N/A | N/A | N/A |
|---|
| Product | $56M | $104M | $191M | $301M | $303M | $376M |
|---|
| Research and Development Services | $1M | $1M | $10M | $10M | N/A | N/A |
|---|
| Royalty | $89M | $204M | $360M | $448M | $571M | $868M |
|---|
| Sales-based milestone | $15M | $50M | $10M | $0 | $30M | $70M |
|---|
| Upfront fees | $37M | $42M | $30M | $2M | N/A | N/A |
|---|
| Upfront Fees | N/A | N/A | N/A | N/A | $27M | $18M |
|---|
| $119M |
| $110M |
| UNITED STATES | $19M | $31M | $77M | $52M | $196M | $40M |
|---|
| $267.59M |
| +$71.60M |
| +36.53% |
| 2019 | $195.99M | +$44.13M | +29.06% |
| 2018 | $151.86M | ($164.75M) | (52.04%) |
| 2017 | $316.61M | +$169.92M | +115.84% |
| 2016 | $146.69M | +$11.63M | +8.61% |
